Aligos Therapeutics (ALGS) Return on Capital Employed (2021 - 2025)
Historic Return on Capital Employed for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 0.87%.
- Aligos Therapeutics' Return on Capital Employed rose 3500.0% to 0.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87%, marking a year-over-year increase of 3500.0%. This contributed to the annual value of 1.0% for FY2024, which is 3000.0% down from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Return on Capital Employed is 0.87%, which was up 3500.0% from 0.64% recorded in Q2 2025.
- Over the past 5 years, Aligos Therapeutics' Return on Capital Employed peaked at 0.61% during Q4 2021, and registered a low of 1.55% during Q4 2024.
- In the last 5 years, Aligos Therapeutics' Return on Capital Employed had a median value of 0.84% in 2025 and averaged 0.91%.
- Per our database at Business Quant, Aligos Therapeutics' Return on Capital Employed crashed by -6200bps in 2024 and then soared by 3500bps in 2025.
- Over the past 5 years, Aligos Therapeutics' Return on Capital Employed (Quarter) stood at 0.61% in 2021, then tumbled by -31bps to 0.8% in 2022, then dropped by -16bps to 0.93% in 2023, then tumbled by -67bps to 1.55% in 2024, then soared by 44bps to 0.87% in 2025.
- Its Return on Capital Employed was 0.87% in Q3 2025, compared to 0.64% in Q2 2025 and 0.94% in Q1 2025.